Cancer Protein Description
This report provides a detailed description of a selected cancer protein with information collected from various sources, including UniProt, the Wellcome Trust Sanger Institute’s Catalogue of Somatic Mutations in Cancer (COSMIC), and the Atlas of Genetics and Cytogenetics in Oncology and Haematology.
| Protein Name: | ERAS |
| Gene Name: | ERAS |
| Protein Full Name: | GTPase ERas |
| Alias: | Embryonic stem cell-expressed Ras |
| Mass (Da): | 25287 |
| Number AA: | 233 |
| UniProt ID: | Q7Z444 |
| Locus ID: | 3266 |
| COSMIC ID: | ERAS |
| Gene location on chromosome: | Xp11.23 |
| Cancer protein type: | OP |
| Effect of cancer mutation on protein: | UNCLEAR |
| Effect of active protein on cancer: | PROMOTES |
| Number of cancer specimens: | 20339 |
| Percent of cancer specimens with mutations: | 0.19 |
| Normal role description: | ERAS is a Ras-like monomeric G-protein which posses intrinsic GTPase activity. Ras G-proteins are involved in activating cell growth/proliferation and dysfunction in Ras has been observed in many cancers. ERAS is expressed predominantly in embryonic stem cells during development. ERAS contains variations in its primary sequence which confers a constitutively activated form of Ras with up to 95% of ERAS proteins being in the GTP-bound form. ERAS was found to initiate PI3K signalling and ERAS embryonic stem cells exhibited decreased growth and oncogenic properties. Thus ERAS functions as an oncogene in cancer development. |
| Commentary on involvement of protein in cancer: | Less than 3% mutation in lung. |